Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis

被引：21

作者：

Choi, In Ah ^{[1
]}

Lee, Sang Jin ^{[2
,3
]}

Park, Won ^{[4
]}

Park, Sung Hwan ^{[5
]}

Shim, Seung-cheol ^{[6
]}

Baek, Han Joo ^{[7
]}

Yoo, Dae-Hyun ^{[8
]}

Kim, Hyun Ah ^{[9
]}

Lee, Soo Kon ^{[10
]}

Lee, Yun Jong ^{[11
]}

Park, Young Eun ^{[12
]}

Cha, Hoon-Suk ^{[13
]}

Lee, Eun Young ^{[14
]}

Lee, Eun Bong ^{[14
]}

Song, Yeong Wook ^{[2
,3
]}

机构：

[1] Chungbuk Natl Univ Hosp, Dept Internal Med, Cheongju, South Korea

[2] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Grad Sch Convergence Sci & Technol, Seoul 03080, South Korea

[3] Seoul Natl Univ, Coll Med, Med Res Inst, Seoul 03080, South Korea

[4] Inha Univ Hosp, Dept Internal Med, Incheon, South Korea

[5] Catholic Univ Korea, Dept Internal Med, Seoul St Marys Hosp, Seoul, South Korea

[6] Chungnam Natl Univ Hosp, Dept Internal Med, Daejeon, South Korea

[7] Gachon Univ, Dept Internal Med, Gil Med Ctr, Incheon, South Korea

[8] Hanyang Univ, Dept Internal Med, Med Ctr, Seoul, South Korea

[9] Hallym Univ, Dept Internal Med, Med Ctr, Anyang, South Korea

[10] CHA Bundang Med Ctr, Dept Internal Med, Seongnam, South Korea

[11] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea

[12] Pusan Natl Univ Hosp, Dept Internal Med, Busan, South Korea

[13] Sam Sung Med Ctr, Dept Internal Med, Seoul, South Korea

[14] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

来源：

ARCHIVES OF RHEUMATOLOGY | 2018年 / 33卷 / 04期

关键词：

Arthritis; interleukin-6; interleukin-33; rheumatoid; tocilizumab; IL-33; METHOTREXATE; PATHOGENESIS; CYTOKINES; ANTIBODY; RECEPTOR; PLACEBO; CELLS;

D O I：

10.5606/ArchRheumatol.2018.6753

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: This study aims to examine the effects of tocilizumab therapy on serum levels of interleukin (IL)-33 and IL-6 in rheumatoid arthritis (RA) patients. Patients and methods: Interleukin-33 and IL-6 levels in serum samples from 83 RA patients (10 males, 73 females; mean age 51.9 years; range, 26 to 77 years) and 12 healthy controls (2 males, 10 females; mean age 52.2 years; range, 39 to 62 years) were compared by cross-sectional, case control analysis. Of the RA patients, 40 received 24 weeks of tocilizumab therapy and were assigned to the prospective cohort. These 40 patients were then divided into two subgroups as responders and non-responders according to the American College of Rheumatology (ACR) 20. The remaining 43 RA patients did not receive tocilizumab therapy. Serum cytokine levels were analyzed at baseline and after 24 weeks of tocilizumab therapy in these patients. Results: Interleukin-33 and IL-6 concentrations were significantly higher in RA patients than in healthy controls (p<0.001 for both). Serum IL-33 levels in RA patients showed a significant correlation with rheumatoid factor titer (r=0.660, p<0.001), and IL-6 levels showed a significant correlation with high-sensitivity C-reactive protein levels (Spearman's rank correlation coefficient=0.482, p<0.001). Serum IL-33 levels decreased significantly after 24 weeks of tocilizumab therapy (p<0.001); this was particularly marked in ACR20 responders (p<0.001). However, the decrease in non-responders was not significant (p=0.066). Changes in serum IL-6 levels after 24 weeks of tocilizumab therapy were not significant in either ACR20 responders or non-responders. Conclusion: Serum IL-33 levels in RA patients receiving tocilizumab therapy decreased significantly, particularly in ACR20 responders. Thus, IL-33 may be a useful marker for monitoring responses to tocilizumab therapy.

引用

页码：389 / 394

页数：6

共 19 条

[1] The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders [J].